AIFFFirefly Neuroscience, Inc.
The schedule
- Thu15Oct
High risk of an equity raise to fund operations given the limited cash position.
- Mon16Nov
Crucial clinical utility data for the neurodiagnostic platform to drive commercial adoption.
- Tue15Dec
Securing a partnership would provide non-dilutive funding and industry validation.
- Fri12Feb
Focus shifts to post-financing execution and initial commercial momentum from September data.
- Fri14May
Year-end results set the tone for FY27, demanding a sustainable path to profitability.
- Fri13Aug
Past
- Fri11Sep
Actual outcome: Bull · $1.54 at outcome
AIFF delivered a significant earnings surprise, exceeding expectations with strong revenue and EPS growth. The company provided upbeat guidance for the upcoming quarters, signaling robust demand and operational efficiency. This move reflects improved investor sentiment and confidence in the company's growth trajectory. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-28: +61.2% from 2026-09-14 (~2.6σ). Target date 2026-09-18 reached; move through 2026-09-28 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-29: +60.7% from 2026-09-15 (~2.5σ). Target date 2026-09-18 reached; move through 2026-09-29 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-30: +64.7% from 2026-09-16 (~2.7σ). Target date 2026-09-18 reached; move through 2026-09-30 observed.
AIFF delivered a significant earnings surprise, exceeding expectations with strong revenue and EPS growth. The company provided upbeat guidance for the upcoming quarters, signaling robust demand and operational efficiency. This move reflects improved investor sentiment and confidence in the company's growth trajectory. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-28: +61.2% from 2026-09-14 (~2.6σ). Target date 2026-09-18 reached; move through 2026-09-28 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-29: +60.7% from 2026-09-15 (~2.5σ). Target date 2026-09-18 reached; move through 2026-09-29 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-30: +64.7% from 2026-09-16 (~2.7σ). Target date 2026-09-18 reached; move through 2026-09-30 observed.
- Fri14Aug
Actual outcome: Mixed · $1.08 at outcome
Firefly Neuroscience reported an EPS actual of -0.13, matching the estimate, and showed a 291% increase in TMS center customer clinical assessments. However, the stock remained flat, likely due to mixed sentiment around the earnings report and lack of clear directional catalysts beyond the reported growth in customer volumes.
Market will scrutinize cash runway and revenue traction from the 1027% YoY growth rate.
- Wed15Jul
Actual outcome: Bear · $1.09 at outcome
Stock fell 6.0% from event to outcome date, aligning with the bear trajectory.
Given a small cash balance and ongoing losses, Firefly Neuroscience is likely to explore an equity financing or similar capital raise over the next 12 months. A comparatively bullish outcome would see the company raise capital on acceptable terms with limited discount, leaving the stock closer to $1.40 once the deal is absorbed. A bearish outcome would be a deeply discounted or highly dilutive transaction that shakes confidence and drives the stock toward $1.40.